)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Orthocell
Orthocell (OCC) investor relations material
Orthocell AGM 2026 presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 presentation summary5 Nov, 2026
Opening remarks and agenda
Chair John Van Der Wielen acknowledged shareholder disappointment with the share-price response despite progress, and reiterated a focus on execution, growth and long-term value.
FY2026 marked a continued shift from development-stage biotech toward commercial execution and growth.
Financial performance review
FY2026 revenue grew 45% YoY; funds available were A$39.0M at 30 September 2026, with no long-term secured debt.
Q1 FY2027 operating cash use was A$4.5M and normalised cash use A$3.9M; no additional funding was anticipated to support Remplir commercialisation and reach profitability.
October 2026 U.S. Remplir sales were 92 units and A$279,000, 84% above the Q1 FY2027 monthly average of 50 units.
Board and executive committee updates
Chair John Van Der Wielen said the strategy, commercial platform and balance sheet positioned the business for its next growth phase; he thanked CEO Paul Anderson, directors, staff, clinicians, partners, distributors and shareholders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Orthocell
- Remplir sales grew, U.S. adoption expanded and A$39.0M in funds supports execution.OCC
Q1 2027 - FY24 revenue up 31%, global expansion of Striate+ and Remplir, strong cash, no debt.OCCCompany presentation
- FDA-cleared Remplir targets the $1.6B US nerve repair market with strong clinical and financial backing.OCCInvestor presentation
- US sales ramp up, breakeven in sight, and global expansion supported by strong funding.OCCInvestor presentation
- Record 45% revenue growth and strong US expansion, with A$44M in available funds.OCCH2 2026
- Record revenue growth and strong liquidity support ongoing global expansion.OCCQ4 2026 TU
- Record revenue growth and global expansion driven by innovative collagen medical devices.OCCAGM 2024 presentation
- First US surgical use achieved, with sales ramp-up and strong clinical results supporting growth.OCCInvestor presentation
- US Remplir launch accelerates revenue growth, with robust pipeline and global expansion plans.OCCAGM 2025 presentation
Next Orthocell earnings date
Q2 202722 Feb, 2027
Orthocell
Next Orthocell earnings date
Q2 202722 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)